No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Guggenheim Reiterates Buy on Verve Therapeuticsto Buy
Verve Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Promising Outlook for Verve Therapeutics: FDA Clearance and Strategic Partnership Drive Buy Rating
William Blair Maintains Verve Therapeutics(VERV.US) With Buy Rating
William Blair Remains a Buy on Verve Therapeutics (VERV)
Verve Therapeutics Shares Are Trading Higher After the Company Received FDA Approval to Begin Cholesterol Treatment Trial.
Unlock the Full List